摘要:

The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (DeltaAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased DeltaAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher DeltaAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.

附注:

Gao, Xu Colicino, Elena Shen, Jincheng Just, Allan C Nwanaji-Enwerem, Jamaji C Wang, Cuicui Coull, Brent Lin, Xihong Vokonas, Pantel Zheng, Yinan Hou, Lifang Schwartz, Joel Baccarelli, Andrea A eng R01 ES025225/ES/NIEHS NIH HHS/ R01 ES021733/ES/NIEHS NIH HHS/ P30 ES023515/ES/NIEHS NIH HHS/ R01 ES027747/ES/NIEHS NIH HHS/ F31 AG056124/AG/NIA NIH HHS/ R00 ES023450/ES/NIEHS NIH HHS/ P30 ES009089/ES/NIEHS NIH HHS/ Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Aging (Albany NY). 2018 Nov 10;10(11):3210-3228. doi: 10.18632/aging.101626.

Website